Results 21 to 30 of about 18,351 (216)

Quantum chemistry calculation aided design of chiral ionic liquid-based extraction system for amlodipine separation [PDF]

open access: yes, 2018
Amlodipine is a widely used medication in treating hypertension, which is also known as a chiral compound. So far efforts have been made to obtain optically pure (S)-amlodipine because (R)-amlodipine has poor efficacy and is ...
Becke   +48 more
core   +1 more source

Blood pressure control versus atrial fibrillation management in stroke prevention [PDF]

open access: yes, 2015
Hypertension is one of the major risk factors for atrial fibrillation which in turn is the most prevalent concomitant condition in hypertensive patients. While both these pathological conditions are independent risk factors for stroke, the association of
Sada, Lidia   +2 more
core   +1 more source

The Effect of Visual Media Education in the Management Therapy on the Level of Knowledge of Patients Diabetes Mellitus with Comorbid [PDF]

open access: yes, 2023
Diabetes Mellitus (DM) is a group of metabolic diseases characterized by hyperglycemia that occurs due to abnormalities in insulin secretion, insulin action or both and is often accompanied by increased blood pressure.
Devi Ristian Octavia   +1 more
core   +2 more sources

Asymmetric addition of chiral boron-ate complexes to cyclic iminium ions [PDF]

open access: yes, 2014
Boron-ate complexes derived from enantioenriched secondary benzylic boronic esters and aryl lithiums have been reacted with quinolinium, pyridinium and dihydroisoquinolinium salts to give enantioenriched heterocyclic structures with very high ...
Aggarwal, Varinder K.   +4 more
core   +2 more sources

Effects of S-Amlodipine in the Management of Hypertension in Mongolian Patients

open access: yesCardiology and Angiology: An International Journal, 2022
Objective: To evaluate the efficacy and safety of S-Amlodipine in patients suffering from hypertension. Materials and Methods: A multicenter, prospective, open-label, non-comparative, clinical trial was conducted on 364 patients with hypertension in Mongolia.
Namita Anchan   +4 more
openaire   +1 more source

Generic versus brand-name drugs used in cardiovascular diseases [PDF]

open access: yes, 2016
This meta-analysis aimed to compare the efficacy and adverse events, either serious or mild/moderate, of all generic versus brand-name cardiovascular medicines.
Boccia, Stefania   +9 more
core   +1 more source

New cerebrovascular agent with hypotensive activity [PDF]

open access: yesResearch Results in Pharmacology, 2019
Introduction: In cerebrovascular disorders, special attention is paid to a hypertensive cerebrovascular crisis, which combines a vascular injury of the brain and hypertension.
Galina A. Kim   +5 more
doaj   +3 more sources

Stereoselective Biotransformation: Transfer of Learning to Advance Drug Metabolism and Biocatalysis

open access: yesAngewandte Chemie, EarlyView.
Understanding stereoselective biotransformations has implications for predicting drug disposition and response and may also inspire novel biocatalytic and biomimetic strategies to address challenges in metabolite and API synthesis. ABSTRACT Chirality is an important determinant of drug action, as enantiomers can exhibit markedly different ...
Grace A. Okunlola, Godwin A. Aleku
wiley   +2 more sources

COMPARATIVE STUDY OF EFFICIENCY AND SAFETY OF THE NEW DRUG OF AMLODOPINE – S-AMLODOPINE IN PATIENTS WITH ARTERIAL HYPERTENSION OF I-II DEGREE

open access: yesРациональная фармакотерапия в кардиологии, 2016
Aim. To evaluate efficacy and safety of a new drug of amlodipine – S-amlodipine (Azomex, Emcur, India) compared to original drug of racemic amlodipine (Norvasc, Pfizer, USA) in patients with arterial hypertension (HT) of I-II grade.Material and methods ...
M. A. Maksimova   +5 more
doaj   +1 more source

Pattern of adverse drug reactions reported at a tertiary health care teaching hospital of Tripura: a retrospective study [PDF]

open access: yes, 2016
Background: ADR monitoring and reporting activity is in its infancy in India. India rates below 1% in pharmacovigilance as against the world rate of 5%. India is the fourth largest producer of pharmaceuticals in the world.
., Lalromawii   +4 more
core   +6 more sources

Home - About - Disclaimer - Privacy